The London Life Sciences Team advised ReViral on its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to $525 million, including up front and development milestones.
ReViral is a privately held clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising novel antiviral therapeutics that target respiratory syncytical virus (“RSV”). RSV is a respiratory pathogen, which can lead to severe and life-threatening lower respiratory tract infections in high-risk populations, including young infants, immunocompromised individuals, and older adults. It is estimated to cause infections in approximately 64 million people, resulting in about 160,000 deaths, globally each year.
Pfizer is an American multinational pharmaceutical and biotechnology company. The acquisition expands Pfizer’s innovative anti-infective pipeline and leverages R&D capabilities, manufacturing and commercialization expertise to potentially address a significant unmet need for the treatment of RSV.
The Goodwin team was led by Graham Defries with Kenny Walker-Durrant, Jack Christian and Robert Coleman-Lee (Corporate Life Sciences), Tim Worden and Lucy Sharples (Intellectual Property), Katie Leah, and Nathan Langford (Tax) and Sarah Jordan (Competition).
For more information please see here.